Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer

Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Holder, S L, Drabick, J, Zhu, J, Joshi, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Journal Clubs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/
https://www.ncbi.nlm.nih.gov/pubmed/25756508
http://dx.doi.org/10.1080/15384047.2014.1002687
_version_ 1782397606968688640
author Holder, S L
Drabick, J
Zhu, J
Joshi, M
author_facet Holder, S L
Drabick, J
Zhu, J
Joshi, M
author_sort Holder, S L
collection PubMed
description Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone.
format Online
Article
Text
id pubmed-4622618
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-46226182016-03-10 Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer Holder, S L Drabick, J Zhu, J Joshi, M Cancer Biol Ther Journal Clubs Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone. Taylor & Francis 2015-03-10 /pmc/articles/PMC4622618/ /pubmed/25756508 http://dx.doi.org/10.1080/15384047.2014.1002687 Text en © 2015 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Journal Clubs
Holder, S L
Drabick, J
Zhu, J
Joshi, M
Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title_full Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title_fullStr Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title_full_unstemmed Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title_short Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
title_sort dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
topic Journal Clubs
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622618/
https://www.ncbi.nlm.nih.gov/pubmed/25756508
http://dx.doi.org/10.1080/15384047.2014.1002687
work_keys_str_mv AT holdersl dexamethasonemaybethemostefficaciouscorticosteroidforuseasmonotherapyincastrationresistantprostatecancer
AT drabickj dexamethasonemaybethemostefficaciouscorticosteroidforuseasmonotherapyincastrationresistantprostatecancer
AT zhuj dexamethasonemaybethemostefficaciouscorticosteroidforuseasmonotherapyincastrationresistantprostatecancer
AT joshim dexamethasonemaybethemostefficaciouscorticosteroidforuseasmonotherapyincastrationresistantprostatecancer

Ejemplares similares